Clinical research
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR.
New data presented at the IASLC 2020 North America Conference on Lung Cancer shows a combination of Keytruda with other medications has a positive impact on non-small cell lung cancer.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Pfizer will not seek Emergency Use Authorization for its COVID-19 vaccine until the end of November even if the readout from a Phase III study expected later this month is positive.
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair.
Putin touts efficacy and safety of new vaccine without the data to back him up.
Cyclerion is a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases affecting the central nervous system (CNS).
Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.
Eli Lilly announced that it is pausing its clinical trial of a combination antibody against COVID-19 over safety concerns. Typically, this would be because a patient or volunteer showed a serious side effect or became sick, but the company did not clarify what the reason for the pause is.
PRESS RELEASES